ArtVentive Medical Group Inc. officials announce that the company has received its European CE Mark certification for the ArtVentive EOS Peripheral Vascular Enoluminal Occlusion system.
"This is a very significant achievement in the company's history as it moves toward commercialization and its planned launch into the European markets," states Dr. Leon Rudakov, president and CTO. "The CE Mark also paves the way to facilitate approvals for the ArtVentive EOS device internationally in meeting with the Company's global mandate," states Jim Graham, CEO and chairman.
ArtVentive Medical Group Inc., with its corporate headquarters in Carlsbad, Calif., is an innovative, multi-faceted medical device corporation committed to developing, manufacturing and marketing a family of endoluminal occlusion devices (EOS).
The ArtVentive EOS system encompasses strategically innovative cutting edge devices that are unique, internationally patented and trademarked. The EOS device is catheter based and self-expandable serving for permanent or temporary (reversible) occlusion of body lumens (a cavity found within the vascular system and organ network within the body). The revolutionary device is based on a proprietary technology platform and will serve in many cases as a safe and reliable alternative to major surgery. This inventive breakthrough in technology is bringing the current interventional, image-guided techniques to a new level of sophistication, resolving significant and unaddressed health issues.
The ArtVentive EOS device targets a substantive multi-billion dollar market demand in several major clinical areas including peripheral, neurovascular, women's health (minimally invasive contraceptive device), interventional cardiology, and pulmonary health issues.